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ABSTRACT
Objective: To determine whether rheumatoid factor (RF),
anti-cyclic citrullinated peptide (CCP) antibodies, or
carriage of shared epitope (SE) and PTPN22 genetic
susceptibility variants predict response to therapy in
patients with rheumatoid arthritis (RA) treated with anti-
tumour necrosis factor (TNF) agents.
Methods: UK-wide multicentre collaborations were
established to recruit a large cohort of patients treated
with anti-TNF drugs for RA. Serum RF, anti-CCP antibody
and SE status were determined using commercially
available kits. PTPN22 R620W genotyping was performed
by Sequenom MassArray. Linear regression analyses
were performed to investigate the role of these four
factors in predicting response to treatment by 6 months,
defined as the absolute change in 28-joint Disease
Activity Score (DAS28).
Results: Of the 642 patients analysed, 46% received
infliximab, 43% etanercept and 11% adalimumab. In all,
89% and 82% of patients were RF and anti-CCP positive,
respectively. Patients that were RF negative had a 0.48
(95% CI 0.08 to 0.87) greater mean improvement in
DAS28 compared to patients that were RF positive. A
better response was also seen among patients that were
anti-CCP negative. No association was demonstrated
between drug response and SE or PTPN22 620W
carriage.
Conclusion: The presence of RF or anti-CCP antibodies
was associated with a reduced response to anti-TNF
drugs. However, these antibodies only account for a small
proportion of the variance in treatment response. It is
likely that genetic factors will contribute to treatment
response, but these do not include the well established
RA susceptibility loci, SE and PTPN22.
To date, three anti-tumour necrosis factor (TNF)
biological agents have been approved for the treat-
ment of rheumatoid arthritis (RA), namely etaner-
cept.
1 Collectively these drugs have become one of
the most effective methods of treating RA, with
nearly half of all treated patients achieving an
American College of Rheumatology 20% (ACR20)
improvementlevel orhigher.However,thereisstilla
substantial proportion of patients who show partial
or no response to anti-TNF therapy. With treatment
limitedbyexpensiveannualcostsinmanycountries,
a number of studies have investigated predictors of
response in treated patients.
2–4 For example, analyses
in a large-scale longitudinal observational study
cohort identified lower baseline health assessment
questionnaire (HAQ) scores and concurrent treat-
ment with disease-modifying antirheumatic drugs
(DMARDs) as predictors of greater response rates,
although the latter was only significant in the group
of patients treated with etanercept.
4
Serological and genetic factors are also likely to
contribute towards drug response. Several small
studies (sample sizes ,130) have investigated the
utility of autoantibodies, including rheumatoid
factor (RF) and anti-cyclic citrullinated peptide
(anti-CCP), for predicting response to treatment
with biological agents but results have been
inconsistent.
2356 Similarly, studies have investi-
gated the role of genetic polymorphisms in the
genes encoding TNF,
7–12 interleukin (IL)1b and the
IL1-receptor antagonist,
11 13 IL10,
13 14 transforming
growth factor (TGF)b1
13 and FccRIIIA
15 16 with
inconsistent findings. In particular, a significant
association was demonstrated between carriage of
the shared epitope (SE) and response to etanercept
in a cohort of 200 patients in the USA
12 but was
not replicated in a smaller study of 123 patients
from Sweden.
13 Furthermore, no association of SE
status with response to infliximab treatment was
observed in two European populations (78 patients
from Spain and 198 patients from France).
11 17
However, most of these studies were hindered by
small sample sizes resulting in limited power to
detect modest effects. In this study we established
a UK-wide multicentre collaboration to recruit a
large cohort of patients treated with anti-TNF
agents and tested the hypothesis that confirmed
RA susceptibility factors, namely RF, anti-CCP, SE
and PTPN22 620W, are associated with clinical
response in patients treated with anti-TNF.
METHODS
Patient selection
UK-wide multicentre collaborations were estab-
lished to recruit patients treated with anti-TNF
drugs for RA. Eligible patients from each centre
were subsequently identified from the British
Society of Rheumatology’s (BSR) Biologics
Register (BR).
18 This register compiles extensive
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biological agent and follows them prospectively, on a 6-monthly
basis for 5 years, in order to monitor and determine the
incidence of potential short and long term hazards. The
following criteria were used for the selection of patients for
the current study: (1) currently actively participating in the
BSRBR long-term safety study, (2) doctor-confirmed diagnosis
of RA, (3) currently or have been treated with one of the three
anti-TNF biological agents, (4) European Caucasian descent and
(5) reached 6 months of follow-up. Patients who stopped
treatment temporarily during the first 6 months of therapy
were excluded from selection. Similarly, patients who discon-
tinued therapy prior to the 6-month follow-up for any reason
other than inefficacy were excluded from selection.
Patient recruitment and sample collection
Eligible patients from each collaborating centre were invited to
take part in the study. Additional blood samples were obtained
from consenting patients when they required a blood test as
part of routine care. The additional blood samples and signed
consent forms were posted to the Arthritis Research Campaign
(arc) Epidemiology Unit for processing and storage. For the
majority of patients, two samples of blood were taken: one for
serum and one for DNA extraction. DNA was isolated using a
standard phenol/chloroform extraction method. Serum and
DNA samples were stored at 280uC. UK Central Office of
Research Ethics Committees (COREC) approval (04/Q1403/37)
was obtained for the study.
Clinical information
Clinical and demographic data held on the BSRBR database was
extracted, with the consultants’ permission, and compiled for
each consenting patient. Disease activity was measured using
the 28-joint count disease activity score (DAS28).
19
Immunogenetics
Serum RF and anti-CCP antibody titre were measured using
commercially available kits (RF-PAIA Immunoturbidimetric
Assay for rheumatoid factor, Diastat Anti-CCP Kit (Axis-
Shield Diagnostics, Dundee, UK)). Patients with titres >40 U/
ml and >5U / ml were defined as positive for RF and anti-CCP
antibodies, respectively. HLA-DRB1 typing was performed
using commercially available kits (Dynal RELI SSO HLA-
DRB1 Typing Kit (Dynal Biotech, Wirral, UK)). The SE was
defined as the presence of any of the following alleles: human
leukocyte antigen (HLA)-DRB1*0101, *0102, *0104, *0401,
*0404, *0405, *0408 or *1001. In addition, PTPN22 R620W
(1858C/T) genotyping was performed using mass spectrometry
(Sequenom, Cambridge, UK) as recommended by the manu-
facturer.
Analysis
The primary outcome measure was absolute change in DAS28
between baseline and 6 months. Linear regression analyses were
performed to investigate association between change in DAS28
and RF, anti-CCP status, SE and PTPN22*620W carriage. For the
purposes of this analysis, the recorded 6-month DAS28 score
was used whether patients had discontinued therapy or not.
Analyses were adjusted for baseline DAS28, baseline HAQ score,
administration of concurrent DMARDs and gender, as these
factors have previously been shown to be significant indepen-
dent predictors of response in the BSRBR cohort as a whole and
were also associated in the current cohort (see supplementary
material).
4 Analyses were repeated excluding any patients with
previous exposure to a biological drug, whether or not it was the
same agent. In addition, interaction analyses were performed to
determine whether any observed effects were similar across the
two major drug types, namely etanercept and infliximab.
Patients treated with adalimumab were excluded from this
latter analysis due to the small numbers in this subgroup.
Finally, the European League Against Rheumatism (EULAR)
improvement criteria was assessed as a secondary outcome
measure using logistic regression analyses and applying the
same model as described above.
20 Power calculations were
performed using Quanto (http://hydra.usc.edu/gxe).
21
RESULTS
Patient recruitment
Collaborations were established with 20 rheumatology centres
across the UK from which 1485 patients receiving anti-TNF
therapy for RA satisfied the study inclusion criteria. Of these,
1292 responded to the invitation letter (87%) with 1195 patients
willing to take part (80%). DNA samples were extracted and
available for the first set of 642 patients to be recruited, which
were utilised in the current analysis.
Baseline characteristics and immunogenetics
Baseline characteristics for the group of 642 patients are
presented in table 1. Clinical and demographic measures were
comparable to those previously reported across the BSRBR
dataset as a whole, indicating that this cohort was representa-
tive of the larger anti-TNF-treated RA population in the UK.
22
Genotyping of the PTPN22 R620W (C1858T) polymorphism
and SE was successfully performed in 96% and 83% of patients,
respectively (table 2). Given the frequencies, there was more
than 90% power to detect a difference of >0.6 U in the absolute
change in DAS28 following 6 months of therapy at the 5%
significance level, for PTPN22 and SE carriage in the current
cohort. This level of improvement reflects the difference
between non- and moderate-responders, based on the EULAR
criteria. Autoantibody titres were available for 81% of patients
(table 2), providing 77% and 91% power to detect the same
effect described above for RF and anti-CCP positivity, respec-
tively.
Predictors of response
By the first 6 months follow-up, 10% had discontinued
treatment due to inefficacy while 90% continued anti-TNF
therapy. Based on the EULAR improvement criteria, 21% of
patients were non-responders, 52% moderate responders and
27% good responders. The mean change in DAS28 was an
improvement of 2.5 points and this is consistent with data from
the BSRBR as a whole.
22 Baseline and absolute change in DAS28
values were normally distributed across the patient population.
Linear regression analyses were first performed to investigate
association between drug response at 6 months, defined as the
absolute change in DAS28, and the baseline factors listed in
table 1. Of these, baseline DAS28, baseline HAQ score,
concurrent DMARD therapy and gender were significantly
associated with drug response (p(6.2610
–3; see supplementary
material). These findings were expected as associations to these
factors have been previously reported in the BSRBR data, from
which the current cohort was recruited.
4 Thus, in all analyses,
adjustments were made for these baseline factors.
Linear regression analyses were subsequently performed to
investigate association of drug response with RF, anti-CCP, SE
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negative for RF, patients positive for RF demonstrated
significantly less improvement in their DAS28 values following
anti-TNF therapy (coefficient 20.48, 95% CI 20.87 to 20.08,
p=0.018) (table 3). Similarly, patients positive for anti-CCP
antibodies demonstrated significantly less improvement in
DAS28 compared to anti-CCP negative subjects (coefficient
20.39, 95% CI 20.71 to 20.07, p=0.017) (table 3). Repeating
the analysis after exclusion of patients with a previous exposure
to a biological agent did not alter these conclusions (table 3). By
contrast, the difference in anti-TNF treatment response
between patients that were autoantibody positive and negative
was not statistically significantly different when assessed using
logistic regression analyses with the EULAR response criteria as
the outcome measure, although a trend was observed (see
supplementary material). This highlights the greater power of
continuous compared to categorical data for such analyses. No
association was demonstrated between drug response and either
SE or PTPN22*620W carriage, under any model tested (p.0.05)
(table 3 and supplementary material).
The effects of RF and anti-CCP antibodies were investigated
further by performing multivariate linear regression combining
both antibodies, together with previously known predictors
(baseline HAQ, concurrent DMARD therapy and gender). Being
positive for RF and anti-CCP did not better predict response to
anti-TNF therapy (RF only: R
2=0.17, anti-CCP only: R
2=0.17,
RF plus anti-CCP: R
2=0.17). Furthermore, there was no
interaction between these two factors and their association
with drug response (RF*anti-CCP: R
2=0.18, p=0.16).
However, as the majority of patients were positive for both
antibodies, these analyses may be underpowered.
Finally, in order to investigate whether the predictive effects
of RF and anti-CCP antibodies were equal for etanercept and
infliximab response, linear regression was performed including
the interaction between drug type and autoantibody status.
These analyses suggested that, although the effects of RF and
anti-CCP antibodies appeared restricted to patients treated with
infliximab, the effects were not statistically significantly
different between the two major drug types (table 4).
DISCUSSION
The introduction of anti-TNF biological agents has transformed
the management of RA. However, a substantial proportion of
treated patients still demonstrate partial or no response to these
therapies. Previous studies have suggested that the effect of
clinical factors alone in predicting response is relatively
modest.
2–4 Hence, in the current study, we have focused on
genetic and serological markers. In keeping with previous
reports, we have shown that the presence of RF and anti-CCP
antibodies is associated with a significantly reduced improve-
ment in the DAS28 score following 6 months of anti-TNF
therapy. No associations were demonstrated between drug
response and carriage of risk alleles for either of the other two
well established RA susceptibility factors, SE or PTPN22.
There are a number of methodological limitations to the
study, which require discussion. Firstly, although the current
study design may inform predictions of how patients receiving
anti-TNF therapies will respond to those treatments, the lack of
a control group of patients with RA that were not anti-TNF
treated means that the study cannot inform the debate about
whether a patient will respond better to therapy with an anti-
TNF rather than a DMARD treatment.
Secondly, response measures were assessed at 6 rather than
3 months, when clinical decisions regarding the continuation of
therapy are usually made. Consequently, ,10% of patients had
discontinued therapy due to inefficacy prior to the 6-month
follow-up and some will have commenced alternative treatment
to which they may have responded. Hence, the DAS28 at
6 months may not be a true reflection of the DAS28 when the
drug was discontinued. However, this subgroup of patients
generally remained non-responders at 6 months despite possibly
receiving alternative drugs (mean DAS28 improvement at
6 months: 0.8 compared to 2.7 across the remainder of the
cohort). As the study aims to identify predictors of response by
Table 1 Baseline characteristics
Baseline characteristics Etanercept Infliximab Adalimumab Combined
Number of cases 278 (43) 296 (46) 68 (11) 642
Age, years* 57 (11) 58 (11) 59 (12) 57 (11)
No. female 223 (80) 228 (77) 51 (75) 502 (78)
Current smokers 56 (20) 51 (17) 6 (9) 113 (18)
Ever smoked 163 (59) 168 (57) 35 (51) 366 (57)
Disease duration, years* 13 (9) 15 (10) 13 (10) 14 (10)
DAS28* 6.7 (1) 6.7 (1) 6.5 (1) 6.7 (1)
HAQ* 2 (0.6) 2 (0.6) 2 (0.5) 2 (0.6)
Concurrent DMARD(s) 152 (55) 277 (94) 38 (56) 467 (73)
Concurrent steroids 105 (38) 135 (46) 24 (35) 264 (41)
Previous biological 21 (8) 10 (3) 3 (4) 34 (5)
*Values are mean (SD). All other values are n (%).
DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire.
Table 2 Rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP), shared epitope (SE) and PTPN22
status
Etanercept Infliximab Adalimumab Combined
RF positive 219/241 (91) 189/218 (87) 54/62 (87) 462/521 (89)
Anti-CCP positive 206/241 (86) 177/218 (81) 42/62 (68) 425/521 (82)
SE carriage 184/225 (82) 208/261 (80) 40/49 (82) 432/535 (81)
PTPN22 carriage 78/268 (29) 93/287 (33) 17/64 (27) 188/619 (30)
Values are n of positive/total available (% positive).
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remain on treatment, these patients were included in the
analysis although we recognise that this may have resulted in
underestimations of observed effects.
Thirdly, as one of the requirements for prescribing anti-TNF
agents in the UK includes failure of at least two previous
DMARDs, the patients recruited have severe, long-standing RA
with a mean duration of 14 years. As discussed by Hyrich et al,
patients with more severe disease as a result of irreversible joint
damage may be less likely to respond to treatment.
4 In order to
account for this, analyses were repeated adjusting for disease
duration, but this did not change the overall conclusions (see
supplementary material).
Lastly, the serology was measured cross-sectionally at the time
of sample collection, which may have been some time after
commencement of treatment. Previous studies have shown that,
although titres are affected by treatment, status generally is
not.
62 3Based on records held on the BSRBR, antibody status
changed from positive to negative during anti-TNF treatment in
less than 3% of patients included in the current analyses. Hence,
in all the analyses, autoantibody status rather than titre has been
used. It should also be noted that the proportion of patients that
were RF positive in the current study is higher than that reported
previously for the BSRBR cohort as a whole (89% vs 72%,
respectively).
4 This is most likely to be due to differences in data
collection methods: the BSRBR study relies on information being
provided by the contributing doctors whereas, for the purposes of
the current study, RF was remeasured in all patients for whom a
serum sample was available.
Conversely, our study has several advantages over previous
investigations. Importantly, the use of the BSRBR to identify
suitable patients has meant that the subgroup studied is
comparable to the BSRBR in its entirety. As, until relatively
recently, almost all patients receiving an anti-TNF drug in the UK
for RA were included on this register, the cohort studied is likely
toreflect the characteristicsof patients treated withanti-TNF asa
whole, at least in the UK. Furthermore, a wealth of clinical and
demographic data had already been collected, creating a well
characterised cohort. In addition, this is a large cohort, allowing
robust inferences to be drawn. Finally, the use of the DAS28
measure rather than the EULAR response criteria enhances the
powerofthe study todetectassociation withgenetic predictorsof
response in patients with RA treated with anti-TNF.
As no correction for multiple testing was applied in the
current analyses, these results will require validation in similar-
sized cohorts. Nonetheless, the findings support those of smaller
studies in which similar trends between drug response and
baseline RF and anti-CCP antibody titres have been demon-
strated.
236 As discussed by Mewar et al, RF and anti-CCP
antibodies are independent markers of disease severity for RA.
24
Thus the present findings could be interpreted as showing that
those patients with the most severe disease are least likely to
respond to these therapies. Indeed, there is some evidence to
support this hypothesis, as HAQ score, a measure of disability,
was also significantly associated with response. However, RF
and anti-CCP antibody status remained significant predictors of
response even after accounting for markers of severity such as
HAQ and disease duration.
Table 3 Linear regression for rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP), shared epitope (SE) and PTPN22
Predictor n* (%)
Mean DAS28* (SD) Linear regression, coefficient (95% CI) p value
Base Improvement Adjusted 1{ Adjusted 2{
RF negative 59 (11) 6.72 (1) 3.03 (1.7) Ref Ref
RF positive 462 (89) 6.59 (1) 2.43 (1.5) 20.48 (20.87 to 20.08) p=0.02 20.48 (20.89 to 20.07) p=0.02
Anti-CCP negatve 96 (18) 6.61 (1) 2.90 (1.6) Ref Ref
Anti-CCP positive 425 (82) 6.61 (1) 2.40 (1.5) 20.39 (20.71 to 20.07) p=0.02 20.39 (20.72 to 20.06) p=0.02
SE negative 103 (19) 6.65 (1) 2.38 (1.5) Ref Ref
SE positive 432 (81) 6.71 (1) 2.49 (1.5) 0.07 (20.25 to 0.39) p=0.68 0.06 (20.26 to 0.39) p=0.70
PTPN22 negative 431 (70) 6.67 (1) 2.51 (1.6) Ref Ref
PTPN22 positive 188 (30) 6.72 (1) 2.48 (1.4) 20.11 (20.36 to 0.15) p=0.41 20.13 (20.39 to 0.13) p=0.34
*Figures represent those across the complete subgroup of 642 patients. {Initial analyses were performed across the entire cohort, adjusting for baseline DAS28, HAQ, concurrent
DMARD therapy and gender. {Subsequent analyses excluded patients with previous exposure to a biological agent.
DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; Ref, reference group.
Table 4 Linear regression of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP), stratifying for anti-tumour necrosis factor (TNF) agents
Predictor n* (%)
Mean DAS28* (SD) Linear regression coefficient (95% CI) p value
Base Improvement Adjusted{ Difference between drugs
Etanercept: Ref
RF negative 22 (9) 6.63 (1) 2.69 (1.8) Ref
RF positive 219 (91) 6.63 (1) 2.43 (1.5) 20.25 (20.89 to 0.39) p=0.44
Infliximab: 20.58 (21.4 to 0.03) p=0.18
RF negative 29 (13) 6.79 (1) 3.34 (1.6) Ref
RF positive 189 (87) 6.60 (1) 2.34 (1.6) 20.83 (21.40 to 20.27) p=0.004
Etanercept: Ref
Anti-CCP negative 35 (15) 6.62 (1) 2.72 (1.4) Ref
Anti-CCP positive 206 (85) 6.64 (1) 2.40 (1.5) 20.26 (20.77 to 0.26) p=0.33
Infliximab: 20.41 (21.1 to 0.3) p=0.26
Anti-CCP negative 41 (19) 6.62 (1) 3.07 (1.7) Ref
Anti-CCP positive 177 (81) 6.63 (1) 2.33 (1.6) 20.67 (21.16 to 20.18) p=0.007
*Figures represent those across the complete subgroup of 642 patients. {Analyses adjusted for baseline DAS28, HAQ, concurrent DMARD therapy and gender.
DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; Ref, reference group.
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markers of anti-TNF treatment response previously identified,
(concurrent DMARD therapy, baseline HAQ and gender)
2–4
with RF and anti-CCP antibody status data still only accounts
for a small proportion of the variance in drug response
(R
2=17%) and would not be useful in the clinical setting. We
hypothesise that, in addition to these clinical and serological
factors, genetic factors will play a role and the challenge now is
to identify these. No association was observed between
treatment response and carriage of the RA susceptibility allele
of the PTPN22 gene and, in keeping with most previous studies,
no association of treatment response was observed with SE
carriage, a well established RA severity and susceptibility locus.
Several novel RA susceptibility loci have recently been reported
(eg, OLIG3/TNFAIP3, TRAF1/C5 and STAT4), which may also
warrant investigation.
25–28 However, genes contributing to
disease susceptibility may be different to those that determine
response to treatment.
In summary, the presence of RF or anti-CCP antibodies was
associated with a reduced response to anti-TNF drugs in
patients with RA treated with anti-TNF. However, the presence
of these antibodies only accounts for a small proportion of the
variance in treatment response. It is likely that genetic factors
will contribute to determining the response to treatment with
these agents but do not include the well established RA
susceptibility loci, SE or PTPN22.
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